Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanofi IndiaBOM:500674 -0.54%77 EBITDA Margin % is 31.17% as of Mar. 2026, which is 19% above its 10-year median of 26.28. GuruFocus rates BOM:500674 with a GF Score™ of 77/100 and a GF Value™ of ₹4,402.68 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 960 Drug Manufacturers companies, Sanofi India ranks better than 79.37% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sanofi India's EBITDA for the
three
months ended in Mar. 2026 was ₹1,472 Mil. Sanofi India's Revenue for the
three
months ended in Mar. 2026 was ₹4,723 Mil. Therefore, Sanofi India's EBITDA margin for the quarter that ended in Mar. 2026 was 31.17%.
Sanofi India (BOM:500674) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sanofi India EBITDA Margin % Related Terms
Sanofi India EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sanofi India's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500674 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Sanofi India's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi India EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi India's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sanofi India's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi India (BOM:500674) has a EBITDA Margin % of 31.17% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanofi India and its competitors. This is 19% above median its historical median of 26.28. Over the past decade, Sanofi India's EBITDA Margin % has ranged from 23.26 to 45.36. According to the industry distribution chart, Sanofi India ranks #198 out of 960 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Sanofi India's EBITDA Margin % too high?
Sanofi India's current EBITDA Margin % of 31.17% is 19% above median its 10-year median of 26.28. Over the past 10 years, this metric has ranged from a low of 23.26 to a high of 45.36. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Sanofi India's value of 31.17% is 150% above this industry median. Based on the distribution chart, Sanofi India ranks #198 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi India ranks #198 out of 960 companies for EBITDA Margin %. This places Sanofi India in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Sanofi India's value of 31.17% is 150% above this benchmark. Historically, Sanofi India's own EBITDA Margin % has ranged from 23.26 to 45.36 over the past decade. While the company's 10-year median is 26.28 vs. the industry median of 12.47, Sanofi India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi India's current EBITDA Margin % of 31.17% is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanofi India and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi India's current EBITDA Margin % is 31.17%, which is 19% above median its own 10-year median of 26.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,402.68, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current EBITDA Margin % is 31.17%, which is 19% above median its 10-year median of 26.28 and 150% above the Drug Manufacturers industry median of 12.47. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current EBITDA Margin % is 31.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi India (BOM:500674) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued.
The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,402.68.
GuruFocus considers Sanofi India to be Modestly Undervalued.
Key valuation signals for BOM:500674:
EBITDA Margin %: 31.17% (19% above median its 10-year median of 26.28)
GF Value™: ₹4,402.68 vs. price of ₹3,369.25 (23.5% below fair value)
Industry Position: 150% above the Drug Manufacturers median (#198 of 960)
No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score
Get the complete analysis for BOM:500674
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500674 has been successfully added to your 
